Enliven Therapeutics (ELVN) investor relations material

Executive summary

• Focused on clinical-stage development of small molecule therapeutics, prioritizing ELVN-001 for chronic myeloid leukemia (CML), with positive Phase 1 data showing encouraging efficacy and safety, and alignment with FDA on Phase 3 ENABLE-2 trial design; ELVN-002 development discontinued.

• ENABLE-2 Phase 3 trial for ELVN-001 is expected to initiate in the second half of 2026, targeting CML patients previously treated with one or more TKIs.

• No current plans for manufacturing facilities; relies on third-party partners.

• No revenue generated to date; operations funded through equity offerings, private placements, and public offerings, with significant cash reserves as of June 30, 2026.

Financial highlights

• Net loss of $32.5 million for Q2 2026, compared to $25.3 million in Q2 2025; net loss of $55.1 million for the six months ended June 30, 2026, compared to $53.9 million for the same period in 2025.

• Operating expenses increased to $37.2 million in Q2 2026 from $28.6 million in Q2 2025, driven by higher R&D and G&A costs, especially stock-based compensation.

• R&D expenses were $29.0 million and G&A expenses were $8.2 million for Q2 2026.

• Cash, cash equivalents, and marketable securities totaled $895.2 million as of June 30, 2026, providing expected cash runway into 2030.

• No revenue recognized; all income derived from interest and investment income.

Outlook and guidance

• ENABLE-2 Phase 3 trial initiation planned for the second half of 2026, with further FDA discussions and trial design finalization anticipated in Q3 2026.

• Cash reserves expected to fund operations and planned expenditures for at least the next 12 months and potentially into 2030.

• Anticipates continued operating losses and negative cash flows as clinical development progresses, with substantial additional capital required for commercialization.